Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

PURPOSE: Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Conlon, Kevin C., Lugli, Enrico, Welles, Hugh C., Rosenberg, Steven A., Fojo, Antonio Tito, Morris, John C., Fleisher, Thomas A., Dubois, Sigrid P., Perera, Liyanage P., Stewart, Donn M., Goldman, Carolyn K., Bryant, Bonita R., Decker, Jean M., Chen, Jing, Worthy, Tat'Yana A., Figg, William D., Peer, Cody J., Sneller, Michael C., Lane, H. Clifford, Yovandich, Jason L., Creekmore, Stephen P., Roederer, Mario, Waldmann, Thomas A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2015
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268254/
https://ncbi.nlm.nih.gov/pubmed/25403209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3329
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak